Last reviewed · How we verify
humanized anti-HER2 antibody — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
humanized anti-HER2 antibody (humanized anti-HER2 antibody) — Shanghai CP Guojian Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| humanized anti-HER2 antibody TARGET | humanized anti-HER2 antibody | Shanghai CP Guojian Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- humanized anti-HER2 antibody CI watch — RSS
- humanized anti-HER2 antibody CI watch — Atom
- humanized anti-HER2 antibody CI watch — JSON
- humanized anti-HER2 antibody alone — RSS
Cite this brief
Drug Landscape (2026). humanized anti-HER2 antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/humanized-anti-her2-antibody. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab